{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"44"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"30"},{"groupId":"OG003","value":"54"}],"units":"Participants"}],"description":"To study whether intensifying induction, including fractionated cyclophosphamide and thioguanine, in patients with day 15 MRD ≥ 5% will result in improved leukemia cytoreduction in this subgroup compared to therapy followed in the TOTXV protocol.","groups":[{"description":"Patients randomized on the first day of continuation phase to receive 3500 units/m\\^2 dose of PEG-asparaginase","id":"OG000","title":"TOTXVI PEG 3500"},{"description":"Patients randomized on the first day of continuation phase to receive 2,500 units/m\\^2 dose of PEG-asparaginase","id":"OG001","title":"TOTXVI PEG 2500"},{"description":"Patients who came off study prior to randomization","id":"OG002","title":"TOTXVI Not Randomized"},{"description":"Day 15 MRD \\> or equal to 5% in Total XV","id":"OG003","title":"All Eligible Patients in TOTXV"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"We will compare the proportion of patients with Day-15 MRD≥5% on TOTXVI who are Day-42 MRD positive with the proportion of Day-46 MRD positives in the corresponding subgroup in TOTXV by Fisher's exact test.","reportingStatus":"POSTED","timeFrame":"End of remission induction; day 42 in Total XVI and day 46 in Total XV","title":"Proportion of Participants With Minimal Residual Disease (MRD) at End of Remission Induction ≥ 0.01%","type":"SECONDARY","unitOfMeasure":"Participants"}